LDE225 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma, Gorlin Syndrome, Nevoid Basal Cell Carcinoma Syndrome
Trial Timeline
Apr 1, 2011 → Oct 1, 2012
NCT ID
NCT01350115About LDE225 + Placebo
LDE225 + Placebo is a phase 2 stage product being developed by Novartis for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01350115. Target conditions include Basal Cell Carcinoma, Gorlin Syndrome, Nevoid Basal Cell Carcinoma Syndrome.
What happened to similar drugs?
1 of 7 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01350115 | Phase 2 | Completed |
Competing Products
20 competing products in Basal Cell Carcinoma